Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through ...

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...